US FDA Clears Way for Phase 2 Trial of Injectable rhPDGF-BB for Under-eye Hollows

The US Food and Drug Administration (FDA) has greenlit Lynch Regenerative Medicine’s Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in adults with infraorbital hollowing.

The Phase 2 clinical trial is a multi-center, randomized, dose-ranging study to evaluate the safety, tolerability, and preliminary efficacy of rhPDGF-BB injection for the treatment of infraorbital hollowing. Primary endpoints include safety and improvement on the Canfield Infraorbital Hollowing Scale at 12 weeks. Additional endpoints include assessments of improvements to the quality of the infraorbital tissue via validated patient-reported outcome measures and quantitative image analysis, as well as the pharmacokinetic and immunogenicity profile.

The investigation evaluates an injectable rhPDGF-BB solution. LRM separately markets ariessence pure PDGF+, a topical cosmetic product intended to improve the appearance of skin that contains rhPDGF-BB and hyaluronic acid serum. The Phase 2 clinical trial is expected to begin enrollment within the next few weeks.

“The initiation of this Phase 2 study marks an important milestone in the clinical development of injectable PDGF for the bioregenerative treatment of infraorbital hollows. Patients and practitioners continue to seek safe, effective, and durable bioregenerative options for improving volume deficiency and contour irregularities in the tear trough region. We are excited to further evaluate the potential of PDGF in a well-controlled clinical setting and look forward to enrolling patients in this important study,” says Steve Yoelin, MD, an Ophthalmologist in Newport Beach, CA, and Phase 2 Principal Investigator, in a news release.